Cahir-McFarland, Ellen <br/><br/>
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response.  [electronic resource] 

 -  Neurology  08 2016 
 - 958-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1526-632X 
<br/><br/><label>Standard No.: </label>10.​1212/​01.​wnl.​0000496643.​57775.​41  doi